Deferasirox GPO

Deferasirox GPO Drug Interactions

deferasirox

Manufacturer:

GPO

Distributor:

GPO
Full Prescribing Info
Drug Interactions
Metabolism/Transport effects: Deferasirox is a substrate of UGT1A1, inhibits CYP1A2 (moderate) and CYP2C8 (moderate) and induces CYP3A4 (weak/moderate).
Agomelatine: Effect: CYP1A2 inhibitor (moderate) may increase the serum concentration of agomelatine.
Management: Monitor therapy.
Aluminum hydroxide: Effect: May diminish the therapeutic effect of deferasirox.
Management: Avoid combination.
Anticoagulants: Effect: May enhance the adverse/toxic effect of deferasirox. Specifically, the risk of GI ulceration/irritation or GI bleeding may be increased.
Management: Monitor therapy.
Aripiprazole: Effect: CYP3A4 inducers may decrease the serum concentration of aripiprazole.
Management: Double the oral aripiprazole dose and closely monitor clinical response. Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole. Consider therapy modification.
Axitinib: Effect: CYP3A4 inducers (weakly to moderately effective) may decrease the serum concentration of axitinib.
Management: Avoid combination.
Bile acid sequestrants: Effect: May decrease the serum concentration of deferasirox.
Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.
Bisphosphonates derivatives: Effect: May enhance the adverse/toxic effect of deferasirox. Specifically, the risk of GI ulceration/irritation or GI bleeding may be increased.
Management: Monitor therapy.
Corticosteroids: Effect: May enhance the adverse/toxic effect of deferasirox. Specifically, the risk of GI ulceration/irritation or GI bleeding may be increased.
Exceptions: beclomethasone (nasal) budesonide (nasal); ciclesonide (nasal); desonide; dexamethasone (ophthalmic); difluprednate; flunisolide (nasal); fluocinolone (ophthalmic); fluticasone (nasal); loteprednol; mometasone (nasal); prednisolone (ophthalmic); triamcinolone (nasal); triamcinolone (ophthalmic).
Management: Monitor therapy.
Corticosteroids (systemic): Effect: May enhance the adverse/toxic effect of deferasirox. Specifically, the risk of GI ulceration/irritation or GI bleeding may be increased.
Management: Monitor therapy.
CYP1A2, CYP2C8 substrates: Effect: Deferasirox may increase the serum concentration of CYP1A2 and CYP2C8 substrates.
Management: Monitor therapy.
CYP3A4 substrates: Effect: Deferasirox may decrease the serum concentration of CYP3A4 substrates.
Management: Monitor therapy.
Fosphenytoin, phenobarbital, phenytoin, rifampin, ritonavir: Effect: May decrease the serum concentration of deferasirox.
Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing. Consider therapy modification.
Ibrutinib: Effect: CYP3A4 inducers (weakly to moderately effective) may decrease the serum concentration of ibrutinib.
Management: Consider therapy modification.
Nonsteroidal anti-inflammatory drugs (NSAIDs): Effect: May enhance the adverse/toxic effect of deferasirox. Specifically, the risk of GI ulceration/irritation or GI bleeding may be increased.
Management: Monitor therapy.
Pirfenidone: Effect: CYP1A2 inhibitor (moderate) may increase the serum concentration of pirfenidone.
Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes. Avoid combination.
Repaglinide: Effect: Deferasirox may increase the serum concentration of repaglinide.
Management: Monitor therapy.
Saxagliptin: Effect: CYP3A4 inducers may decrease the serum concentration of saxagliptin.
Management: Monitor therapy.
Simeprevir: Effect: CYP3A4 inducers (weakly to moderately effective) may decrease the serum concentration of simeprevir.
Management: Avoid combination.
Theophylline: Effect: Deferasirox may increase the serum concentration of theophylline.
Management: Avoid combination.
Food: Effect: Bioavailability is variably increased when taken with food.
Management: Taken on an empty stomach at the same time each day at least 30 minutes before food. Maintain adequate hydration unless instructed to restrict fluid intake.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in